I like the article but one little piece missing in the jigsaw...How does DES compete with the likes of NWS if it only has a second rate catalogue.That to me is the key to everything.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025